June 5, 2020

The Niche

Knoepfler lab stem cell blog

Search Results for: heart

2 min read

Here in the U.S. we just had our big Thanksgiving holiday, but science goes, stem cells keep growing and needing attention, and it’s another weekend chance to catch up on our paper reading. Here’s this weekend edition of recommended reads including news items and pubs. From Cell Stem Cell: Single-Cell Transcriptome Analysis of Uniparental Embryos Reveals Parent-of-Origin Effects on Human Preimplantation Development. and another there on stem cell machinery in cancer: Humanized Stem Cell Models of Pediatric Medulloblastoma Reveal an Oct4/mTOR Axis that Promotes Malignancy. …Read More

3 min read

In a stunner, Harvard and Brigham & Women’s Hospital reportedly have jointly called for the retraction of 31 papers on heart stem cell research authored by embattled heart stem cell researcher Piero Anversa. The scoop on this by STAT/Retraction Watch written by Ivan Oransky and Adam Marcus gives further details on this mess and past travails of Anversa. He was the prime proponent of the idea of endogenous heart stem cells in adults, but things have gone south since his prime time as a …Read More

2 min read

Where do things stand with IPS cell translational research? The newest development is that regulators in Japan just have given conditional approval to an Osaka University team to an induced pluripotent stem (IPS) cell-based study for ischemic heart disease. For years IPS cell-based products have been on-again off-again in active clinical study for macular degeneration, work led by Dr. Masayo Takahashi. The new heart disease study is led by Yoshiki Sawa. This appears to be the third conditionally approved IPS cell study in Japan. I’m not …Read More

2 min read

How is the stem cell and regenerative medicine biotech sector doing these days and does recent news about specific biotechs such as Capricor suggest issues for the sector more broadly? Capricor had bad news earlier this year related to its stem cells for heart disease program and things just took a turn for the worse this week as pharma giant J&J severed ties with the small California company (here and here). Capricor, which has received more than $17 million in CIRM grant funding, could …Read More

2 min read

Statins have been hailed as some of the best drugs ever. Given the massive, deadly prevalence of cardiovascular disease, some have even semi-jokingly talked about putting statins in the water supply for public health. The growing evidence (e.g. this story) that statins might significantly aid in prevention, delayed progression, or even post-treatment delay of recurrence o cancer seemed to add to the glowing rep of statins. As a prostate cancer survivor, the news on statins and prostate cancer seemed particularly notable. But then another …Read More

2 min read

Stem cell biotech company Bioheart ($BHRT) has had a rough 2015 so far. Could this year be a decisive, negative tipping point for the company? It has a number of clinical trials going, but from my view things seem increasingly uncertain. An oddity amongst stem cell biotechs, Bioheart and its leadership have at times seemed to toy with what some might view as controversial projects. Kristin Comella, CSO of Bioheart, has played a major role in other ventures including in the past with the Ageless Institute, a stem …Read More